November 03, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051
Symbol: LUPIN

BSE Limited
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We are pleased to enclose a Press Release titled "Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States".

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED
AMIT KUMAR GUPTA
Digitally signed by AMIT KUMAR GUPTA
Date: 2026.11.03 19:24:11 +05'30'
AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)

Encl.: a/a.

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States

As the First-To-File, Lupin is Eligible for 180-Day Generic Exclusivity

Mumbai, India, Naples, Fla, November 3, 2026: Global pharma major Lupin Limited (Lupin) today announced the launch of Raltegravir Tablets USP, 600 mg in the United States following the approval from the U.S. FDA for its Abbreviated New Drug Application.

Raltegravir Tablets, 600 mg are bioequivalent to the reference listed drug (RLD) Isentress® HD Tablets, 600 mg of Merck Sharp & Dohme, LLC. and indicated in combination with other antiretroviral agents for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adult patients and in pediatric patients weighing at least 40 kg. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.

Raltegravir Tablets USP, 600 mg (RLD Isentress® HD) had an estimated annual sale of USD 26 million in the U.S. (IQVIA MAT September 2026).

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across India, the U.S., Other Developed Markets, and Emerging Markets, with products distributed in over 100 markets. Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars, and continues to strengthen its market position through a differentiated portfolio. The company maintains strong leadership in the U.S. and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women's health. 15 state-of-the-art manufacturing facilities support sustainable operations, with 6 research centers and a dedicated workforce of over 26,000 professionals. Lupin continues to expand the healthcare ecosystem through diagnostics, digital health, patient-support programs, and disease management initiatives. Sustainability continues to be a core pillar of the company's business strategy.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries, please contact

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com

Elise Titan
Director – U.S. Communications, Lupin
elisetitan@lupin.com

**Safe Harbor Statement*

Isentress® and Isentress® HD are registered trademarks of Merck Sharp & Dohme LLC.